BiopharmaWatch

Portfolios Updated for Q1 2026: biopharmawatch.com/bpw-portfolio BiopharmaWatch Model Portfolios

$ACAD [biopharmawatch.com/company/ACAD] Catalyst Date - [Q1 2026] Drug - ACP-204 Treatment - [Alzheimer's Disease Psychosis] Poa : 12%

Latest catalysts: biopharmawatch.com/fda-calendar $ABVX Catalyst Date - 1Q 2026 Drug - Obefazimod Treatment - Ulcerative colitis (UC) Poa : 55%

$CNTB [2.77$] [-4.31%] [2026-03-30T11:01:00.000Z] Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

Top Market Movers: Negative News Full Access: biopharmawatch.com/market-movers $QNTM [3.96$] [-7.59%] [2026-03-30T11:50:00.000Z] Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

$HOTH [0.82$] [6.52%] [2026-03-31T13:07:00.000Z] Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology

Top Market Movers: Positive News Full Access: biopharmawatch.com/market-movers $SXTP [1.72$] [13.91%] [2026-03-31T11:01:00.000Z] 60 Degrees Pharmaceuticals Announces 2025 Annual Results

$SXTP [biopharmawatch.com/company/SXTP] Catalyst Date - [1Q 2026] Drug - ARAKODA® (tafenoquine) Treatment - [Babesiosis] Poa : 40%

$CNTB [2.77$] [-4.31%] [2026-03-30T11:02:00.000Z] Connect Biopharma Announces $20.2 Million Private Placement Financing

$IMUX [1.10$] [6.80%] [2026-03-31T11:30:00.000Z] Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

$CTNM [biopharmawatch.com/company/CTNM] Catalyst Date - [Q1 2026] Drug - PIPE-791 (LPA1 receptor antagonist) Treatment - [Chronic pain associated with osteoarthritis, low back pain] Poa : 12%

$BIIB [177.14$] [-5.56%] [2026-03-31T00:00:00.000Z] Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

$TNXP [12.93$] [7.48%] [2026-03-31T11:00:00.000Z] Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026

$ALMS [biopharmawatch.com/company/ALMS] Catalyst Date - [2026-01-06] Drug - ESK-001 Treatment - [Moderate-to-severe plaque psoriasis] Poa : 75%

$BIIB [177.14$] [-5.56%] [2026-03-31T10:59:00.000Z] Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

Unusual Volume [biopharmawatch.com/market-movers] Ticker - Avg Vol - Cur Vol - Unusual Ratio $SCYX - 635.6K - 10.1M - 15.89 $LTRN - 835.6K - 12.5M - 14.90 $IOBT - 2.6M - 35.5M - 13.58

Highest Volume [biopharmawatch.com/market-movers] Ticker - Price - Volume $AMN - 19.38$ - $ALHC - 17.12$ - $AKAN - 0.85$ - $ALPS - 1.18$ - $HIMS - 23.84$ - 68.3M

$IBRX [7.33$] [10.14%] [2026-03-31T00:00:00.000Z] ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

$PGEN [3.43$] [-6.54%] [2026-03-30T13:30:00.000Z] Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31

Top Market Movers: Negative News Full Access: biopharmawatch.com/market-movers $CNTB [2.73$] [-20.87%] [2026-03-30T11:02:00.000Z] Connect Biopharma Announces $20.2 Million Private Placement Financing

$SXTP [biopharmawatch.com/company/SXTP] Catalyst Date - [1Q 2026] Drug - ARAKODA® (tafenoquine) Treatment - [Babesiosis] Poa : 40%

Latest catalysts: biopharmawatch.com/fda-calendar $TNXP Catalyst Date - 2026-03-30 Drug - TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody) Treatment - Lyme disease Poa : 15%

$ACXP [3.95$] [5.05%] [2026-03-30T12:01:00.000Z] Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors

Top Market Movers: Positive News Full Access: biopharmawatch.com/market-movers $ICU [3.59$] [31.02%] [2026-03-30T12:20:00.000Z] SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism